US DEA scheduling clears way for launch of Eisai's Lusedra
This article was originally published in Scrip
Executive Summary
The US Drug Enforcement Administration (DEA) has finalised controlled substance classification for Eisai's sedation drug Lusedra (fospropofol), placing it into schedule IV, the second least restrictive category.